50
Participants
Start Date
June 1, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2024
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
RECRUITING
Beijing Friendship Hospital, Beijing
Collaborators (1)
Hangzhou New Horizon Health Technology Co., Ltd.
UNKNOWN
BeOne Medicines
INDUSTRY
Beijing Chao Yang Hospital
OTHER
Xuanwu Hospital, Beijing
OTHER
Tianjin Medical University General Hospital
OTHER
People's Hospital of Tianjin
UNKNOWN
Tianjin Medical University Cancer Institute and Hospital
OTHER
Beijing Friendship Hospital
OTHER